345 related articles for article (PubMed ID: 31571095)
41. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
Saad F; Efstathiou E; Attard G; Flaig TW; Franke F; Goodman OB; Oudard S; Steuber T; Suzuki H; Wu D; Yeruva K; De Porre P; Brookman-May S; Li S; Li J; Thomas S; Bevans KB; Mundle SD; McCarthy SA; Rathkopf DE;
Lancet Oncol; 2021 Nov; 22(11):1541-1559. PubMed ID: 34600602
[TBL] [Abstract][Full Text] [Related]
42. Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis.
Chen X; Wang Q; Pan Y; Wang S; Li Y; Zhang H; Xu M; Zhou H; Liu X
Front Endocrinol (Lausanne); 2023; 14():1134719. PubMed ID: 36967752
[TBL] [Abstract][Full Text] [Related]
43. Novel Androgen Receptor Inhibitors in Non-Metastatic, Castration-Resistant Prostate Cancer: A Systematic Review and Network Meta-Analysis.
Mulati Y; Fan Y; Yu W; Zhang Q; He Z
Front Oncol; 2021; 11():733202. PubMed ID: 34722276
[TBL] [Abstract][Full Text] [Related]
44. Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
Altavilla A; Casadei C; Lolli C; Menna C; Ravaglia G; Gurioli G; Farolfi A; Brighi N; Conteduca V; Burgio SL; Schepisi G; Rossi L; Gargiulo S; Lisotti I; De Giorgi U
Expert Opin Pharmacother; 2020 Dec; 21(17):2091-2099. PubMed ID: 32783772
[TBL] [Abstract][Full Text] [Related]
45. Cost-Utility Analysis of Darolutamide Combined with Androgen Deprivation Therapy for Patients with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China.
Ming J; Wu Y; Han R; Xu X; Waldeck R; Hu S
Adv Ther; 2023 Mar; 40(3):1087-1103. PubMed ID: 36630046
[TBL] [Abstract][Full Text] [Related]
46. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.
Saad F; Cella D; Basch E; Hadaschik BA; Mainwaring PN; Oudard S; Graff JN; McQuarrie K; Li S; Hudgens S; Lawson J; Lopez-Gitlitz A; Yu MK; Smith MR; Small EJ
Lancet Oncol; 2018 Oct; 19(10):1404-1416. PubMed ID: 30213449
[TBL] [Abstract][Full Text] [Related]
47. Managing Nonmetastatic Castration-resistant Prostate Cancer.
Mateo J; Fizazi K; Gillessen S; Heidenreich A; Perez-Lopez R; Oyen WJG; Shore N; Smith M; Sweeney C; Tombal B; Tomlins SA; de Bono JS
Eur Urol; 2019 Feb; 75(2):285-293. PubMed ID: 30119985
[TBL] [Abstract][Full Text] [Related]
48. Darolutamide: An Evidenced-Based Review of Its Efficacy and Safety in the Treatment of Prostate Cancer.
Crawford ED; Stanton W; Mandair D
Cancer Manag Res; 2020; 12():5667-5676. PubMed ID: 32765070
[TBL] [Abstract][Full Text] [Related]
49. Safety differences across androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer.
Shore N; Garcia-Horton V; Terasawa E; Ayyagari R; Grossman JP; Waldeck AR
Future Oncol; 2023 Feb; 19(5):385-395. PubMed ID: 36794575
[TBL] [Abstract][Full Text] [Related]
50. Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16).
Gillessen S; Procopio G; Hayoz S; Kremer E; Schwitter M; Caffo O; Lorente D; Pedrazzini A; Roubaud G; Nenan S; Omlin A; Buttigliero C; Delgado Mingorance JI; González-Del-Alba A; Delgado MT; Nole F; Turco F; Pereira Mestre R; Ribi K; Cathomas R
J Clin Oncol; 2023 Jul; 41(20):3608-3615. PubMed ID: 36753698
[TBL] [Abstract][Full Text] [Related]
51. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
52. The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis.
Zhang X; Zhang G; Wang J; Bi J
Front Endocrinol (Lausanne); 2023; 14():1131033. PubMed ID: 36843606
[TBL] [Abstract][Full Text] [Related]
53. Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.
Higano CS; Beer TM; Taplin ME; Efstathiou E; Hirmand M; Forer D; Scher HI
Eur Urol; 2015 Nov; 68(5):795-801. PubMed ID: 25698064
[TBL] [Abstract][Full Text] [Related]
54. Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile.
Mori K; Quhal F; Katayama S; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Grossmann NC; Rajwa P; Ploussard G; Briganti A; Kimura T; Egawa S; Papalia R; Carrion DM; Fiori C; Shariat SF; Esperto F; Pradere B
Minerva Urol Nephrol; 2022 Jun; 74(3):292-301. PubMed ID: 34308608
[TBL] [Abstract][Full Text] [Related]
55. Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer.
Nakayama H; Sekine Y; Oka D; Miyazawa Y; Arai S; Koike H; Matsui H; Shibata Y; Suzuki K
Prostate; 2022 Feb; 82(3):314-322. PubMed ID: 34843630
[TBL] [Abstract][Full Text] [Related]
56. Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review.
Cattrini C; Caffo O; De Giorgi U; Mennitto A; Gennari A; Olmos D; Castro E
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406564
[TBL] [Abstract][Full Text] [Related]
57. Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease.
Henriquez I; Spratt D; Gómez-Iturriaga A; Abuchaibe O; Couñago F
World J Clin Oncol; 2021 Jan; 12(1):6-12. PubMed ID: 33552935
[TBL] [Abstract][Full Text] [Related]
58. Impact of New Systemic Therapies in Overall Survival in Non-Metastatic Castration Resistant Prostate Cancer: Systematic Review and Meta-Analysis.
Rodriguez-Vida A; Rodríguez-Alonso A; Useros-Rodríguez E; Lopez-Campos F; Amor-Carro O; Arribas-Ruiz A; Martinez-Torres J; Roca-Pardiñas J; Quesada-García A; Muñoz-Del-Toro JR; Juárez-Soto Á
Clin Genitourin Cancer; 2022 Apr; 20(2):197.e1-197.e10. PubMed ID: 34920959
[TBL] [Abstract][Full Text] [Related]
59. Clinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide in Healthy Subjects and Patients with Hepatic or Renal Impairment.
Zurth C; Nykänen P; Wilkinson G; Taavitsainen P; Vuorela A; Huang F; Reschke S; Koskinen M
Clin Pharmacokinet; 2022 Apr; 61(4):565-575. PubMed ID: 34866168
[TBL] [Abstract][Full Text] [Related]
60. nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives.
Berruti A; Bracarda S; Caffo O; Cortesi E; D'Angelillo R; Del Re M; Facchini G; Pappagallo G; Procopio G; Sabbatini R; Santini D
Cancer Treat Rev; 2023 Apr; 115():102525. PubMed ID: 36822009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]